In the past one month, the stock has fallen 10% as against 7.03% decline in the Sensex. It has risen 0.48% in the past one year compared with the Sensex's 28.87% rise.
On a consolidated basis, net profit of Solara Active Pharma Sciences declined 47.57% to Rs 29.71 crore on 1.02% rise in net sales to Rs 401.61 crore in Q2 September 2021 over Q2 September 2020.
Solara Active Pharma Sciences is an API manufacturer. It has two R&D centers and 4 API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities.
